Raymond James & Associates’s Genesis Healthcare, Inc. GEN Stock Holding History

Raymond James & Associates’s Portfolio GEN Stock Details GEN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-55,000	Closed	-$38K	–	3739
2020 Q2	$38K	Hold	55,000	–	–	﹤0.01%	3405
2020 Q1	$46K	Hold	55,000	–	–	﹤0.01%	3325
2019 Q4	$90K	Hold	55,000	–	–	﹤0.01%	3485
2019 Q3	$61K	Hold	55,000	–	–	﹤0.01%	3453
2019 Q2	$68K	Hold	55,000	–	–	﹤0.01%	3466
2019 Q1	$79K	Hold	55,000	–	–	﹤0.01%	3431
2018 Q4	$65K	Hold	55,000	–	–	﹤0.01%	3358
2018 Q3	$74K	Buy	55,000 +30,000	+120%	+$47.5K	﹤0.01%	3470
2018 Q2	$57K	Hold	25,000	–	–	﹤0.01%	3438
2018 Q1	$38K	Hold	25,000	–	–	﹤0.01%	3346
2017 Q4	$19K	Hold	25,000	–	–	﹤0.01%	3348
2017 Q3	$29K	Buy	+25,000	New	+$31.5K	﹤0.01%	3288

Other funds holding GEN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

FWC

First Washington Corp Seattle, Washington $353M AUM 41.46% 1-Year Est. Return

VCM

V3 Capital Management Dallas, Texas $33.4M AUM 5.9% 1-Year Est. Return

Chevy Chase Trust Bethesda, Maryland $34.7B AUM 29.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

Raymond James & Associates's GEN Position: Q3 2020 in Review

Raymond James & Associates sold out of Genesis Healthcare, Inc. (GEN) in Q3 2020, closing a stake of 55,000 shares — an estimated $38K sold.

Raymond James & Associates first reported a position in GEN in Q3 2017 and held it in 12 quarters. The position peaked at $90K in Q4 2019. 55 funds tracked by Wall St. Rank hold GEN as of Q3 2020.

Raymond James & Associates reported no remaining Genesis Healthcare, Inc. position as of Q3 2020 after selling out during the quarter.
Raymond James & Associates sold 55,000 Genesis Healthcare, Inc. shares in Q3 2020, an estimated $38K.
Raymond James & Associates first reported a position in Genesis Healthcare, Inc. in Q3 2017 and held it in 12 quarters.
Raymond James & Associates's Genesis Healthcare, Inc. position peaked at $90K in Q4 2019.
55 funds tracked by Wall St. Rank held Genesis Healthcare, Inc. as of Q3 2020.

Based on Raymond James & Associates's 13F filing for Q3 2020, filed 4 Nov 2020.